Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-st...
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global I...
Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Confer...
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (...
Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well as potential partnerships with established therapies. Corvus recently completed a capital raise, securing $30M with potential for an additional $6...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.